Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 8;9(7):e101819. doi: 10.1371/journal.pone.0101819

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Uttervall et al

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.

PMC Copyright notice

(A) In high-dose treated (HDT) patients with and without renal impairment after 2^nd line of therapy. (B) In non-HDT patients with and without renal impairment after 2^nd line of therapy. (C) Non-HDT patients with renal impairment treated with novel agents (bortezomib, lenalidomide or thalidomide) in the 1^st line compared to those treated with conventional agents (Conv.). (D) Non-HDT-patients with renal impairment treated with bortezomib (Bz) in the 1^st line compared to those treated with conventional agents. (E) HDT-patients with renal impairment treated with novel agents (bortezomib, lenalidomide or thalidomide) in the 1^st line compared to to those treated with conventional agents.